Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and
fluorouracil use different ways to stop tumor cells from dividing so they stop growing or
die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them
or deliver tumor-killing substances to them without harming normal cells. Combining
chemotherapy with trastuzumab may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with
trastuzumab in treating women who have metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC